Daptomycin use in united states children's hospitals

Journal of the Pediatric Infectious Diseases Society

Volumn 4, Issue 1, 2015, Pages 60-62

  Larru, Beatriz ^a   Cowden, Carter L ^a   Zaoutis, Theoklis E ^a,b   Gerber, Jeffrey S ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Children; Daptomycin; MRSA; Resistance; VRE

Indexed keywords

COTRIMOXAZOLE; DAPTOMYCIN; LINEZOLID; RIFAMPICIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL FEATURE; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; ICD-9-CM; LOEFFLER PNEUMONIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; UNITED STATES; HOSPITAL; INFANT; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DAPTOMYCIN; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; INFANT; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TERTIARY CARE CENTERS; UNITED STATES;

EID: 85006216570     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu052     Document Type: Article

References (12)

1. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistantpathogens associated with healthcare-associated infections: summaryof data reported to the National Healthcare Safety Networkat the Centers for Disease Control and Prevention, 2009-2010.Infect Control Hosp Epidemiol 2013; 34:1-14
2. Cosgrove SE. The relationship between antimicrobial resistanceand patient outcomes: mortality, length of hospital stay, andhealth care costs. Clin Infect Dis 2006; 42(suppl 2):S82-9
3. Quist SR, Fierlbeck G, Seaton RA, Loeffler J, Chaves RL.Comparative randomised clinical trial against glycopeptides supportsthe use of daptomycin as first-line treatment of complicatedskin and soft-tissue infections. Int J Antimicrob Agents 2012; 39:90-1
4. Rege S, Mohr J, Lamp KC, Yoon M, Lindfield KC. Safety of daptomycinin patients completing more than 14 days of therapy: resultsfrom the Cubicin® Outcomes Registry and experience. Int JAntimicrob Agents 2013; 41:421-5
5. Chaftari AM, Hachem R, Mulanovich V, et al. Efficacy and safetyof daptomycin in the treatment of Gram-positive catheter-relatedbloodstream infections in cancer patients. Int J Antimicrob Agents2010; 36:182-6
6. Seaton RA, Gonzalez-Ramallo VJ, Prisco V, et al. Daptomycinfor outpatient parenteral antibiotic therapy: a European registryexperience. Int J Antimicrob Agents 2013; 41:468-72
7. Kim PW, Sorbello AF, Wassel RT, Pham TM, Tonning JM,Nambiar S. Eosinophilic pneumonia in patients treated withdaptomycin: review of the literature and US FDA adverse eventreporting system reports. Drug Saf 2012; 35:447-57
8. Palma DM, Giordano S, Neville Cracchiolo A, Zangara V,Coffaro G, Tetamo R. Daptomycin in the treatment of invasiveGram-positive bacterial infections in children: personal experience.Minerva Pediatr 2013; 65:173-8
9. Ardura MI, Mejías A, Katz KS, Revell P, McCracken GH,Sánchez PJ. Daptomycin therapy for invasive Gram-positive bacterialinfections in children. Pediatr Infect Dis J 2007; 26:1128-32
10. Cohen-Wolkowiez M, Watt KM, Hornik CP, Benjamin DK,Smith PB. Pharmacokinetics and tolerability of single-dose daptomycinin young infants. Pediatr Infect Dis J 2012; 31:935-7
11. Hussain A, Kairamkonda V, Jenkins DR. Successful treatment ofmethicillin-resistant Staphylococcus aureus bacteraemia in a neonateusing daptomycin. J Med Microbiol 2011;60:381-383.Available at: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21127158&retmode=ref&cmd=prlinks
12. Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dosepharmacokinetics and tolerability of daptomycin 8 to 10 mg/kgin children aged 2 to 6 years with suspected or provedGram-positive infections. Pediatr Infect Dis J 2011; 30:712-4.